PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
- Resource Type
- article
- Source
- HemaSphere, Vol 6, Pp 1814-1815 (2022)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 - Language
- English
- ISSN
- 2572-9241